CNC Quote, Financials, Valuation and Earnings

CVS Health has a net margin of 1.7% compared to Centene's net margin of 0.09%. Centene's return on equity of 11.5% beat CVS Health's return on equity of 6.68%.

Centene has a consensus price target of $78.92, signalling upside risk potential of 26.05%. On the other hand CVS Health has an analysts' consensus of $64.94 which suggests that it could grow by 41.85%. Given that CVS Health has higher upside potential than Centene, analysts believe CVS Health is more attractive than Centene.

Centene has a beta of 0.448, which suggesting that the stock is 55.17% less volatile than S&P 500. In comparison CVS Health has a beta of 0.595, suggesting its less volatile than the S&P 500 by 40.471%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CVS Health offers a yield of 5.81% to investors and pays a quarterly dividend of $0.67 per share. Centene pays -- of its earnings as a dividend. CVS Health pays out 37.54% of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Centene quarterly revenues are $42B, which are smaller than CVS Health quarterly revenues of $95.4B. Centene's net income of $713M is higher than CVS Health's net income of $87M. Notably, Centene's price-to-earnings ratio is 10.87x while CVS Health's PE ratio is 11.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.21x versus 0.16x for CVS Health. Usually stocks with elevated PS ratios are considered overvalued.

Elevance Health has a net margin of 1.7% compared to Centene's net margin of 2.25%. Centene's return on equity of 11.5% beat Elevance Health's return on equity of 15.67%.

Centene has a consensus price target of $78.92, signalling upside risk potential of 26.05%. On the other hand Elevance Health has an analysts' consensus of $500.87 which suggests that it could grow by 31.55%. Given that Elevance Health has higher upside potential than Centene, analysts believe Elevance Health is more attractive than Centene.

Centene has a beta of 0.448, which suggesting that the stock is 55.17% less volatile than S&P 500. In comparison Elevance Health has a beta of 0.840, suggesting its less volatile than the S&P 500 by 15.968%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elevance Health offers a yield of 1.71% to investors and pays a quarterly dividend of $1.63 per share. Centene pays -- of its earnings as a dividend. Elevance Health pays out 23.3% of its earnings as a dividend. Elevance Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Centene quarterly revenues are $42B, which are smaller than Elevance Health quarterly revenues of $45.1B. Centene's net income of $713M is lower than Elevance Health's net income of $1B. Notably, Centene's price-to-earnings ratio is 10.87x while Elevance Health's PE ratio is 13.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.21x versus 0.51x for Elevance Health. Usually stocks with elevated PS ratios are considered overvalued.

Molina Healthcare has a net margin of 1.7% compared to Centene's net margin of 3.15%. Centene's return on equity of 11.5% beat Molina Healthcare's return on equity of 25.77%.

Centene has a consensus price target of $78.92, signalling upside risk potential of 26.05%. On the other hand Molina Healthcare has an analysts' consensus of $358.46 which suggests that it could grow by 20.91%. Given that Centene has higher upside potential than Molina Healthcare, analysts believe Centene is more attractive than Molina Healthcare.

Centene has a beta of 0.448, which suggesting that the stock is 55.17% less volatile than S&P 500. In comparison Molina Healthcare has a beta of 0.543, suggesting its less volatile than the S&P 500 by 45.712%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molina Healthcare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Centene pays -- of its earnings as a dividend. Molina Healthcare pays out -- of its earnings as a dividend.

Centene quarterly revenues are $42B, which are larger than Molina Healthcare quarterly revenues of $10.3B. Centene's net income of $713M is higher than Molina Healthcare's net income of $326M. Notably, Centene's price-to-earnings ratio is 10.87x while Molina Healthcare's PE ratio is 15.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.21x versus 0.44x for Molina Healthcare. Usually stocks with elevated PS ratios are considered overvalued.

UnitedHealth Group has a net margin of 1.7% compared to Centene's net margin of 6.11%. Centene's return on equity of 11.5% beat UnitedHealth Group's return on equity of 14.51%.

Centene has a consensus price target of $78.92, signalling upside risk potential of 26.05%. On the other hand UnitedHealth Group has an analysts' consensus of $636.78 which suggests that it could grow by 23.83%. Given that Centene has higher upside potential than UnitedHealth Group, analysts believe Centene is more attractive than UnitedHealth Group.

Centene has a beta of 0.448, which suggesting that the stock is 55.17% less volatile than S&P 500. In comparison UnitedHealth Group has a beta of 0.617, suggesting its less volatile than the S&P 500 by 38.345%.

Centene has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UnitedHealth Group offers a yield of 1.59% to investors and pays a quarterly dividend of $2.10 per share. Centene pays -- of its earnings as a dividend. UnitedHealth Group pays out 30.21% of its earnings as a dividend. UnitedHealth Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Centene quarterly revenues are $42B, which are smaller than UnitedHealth Group quarterly revenues of $99.2B. Centene's net income of $713M is lower than UnitedHealth Group's net income of $6.1B. Notably, Centene's price-to-earnings ratio is 10.87x while UnitedHealth Group's PE ratio is 33.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Centene is 0.21x versus 1.23x for UnitedHealth Group. Usually stocks with elevated PS ratios are considered overvalued.